Researchers from Oricell Therapeutics (Shanghai) Co. Ltd. presented the discovery and preclinical characterization of ORIC-613, a dual-targeting CAR T-cell therapy being developed for the treatment of pancreatic and gastric cancer.
Betta Pharmaceuticals Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising a Von Hippel-Lindau disease tumor suppressor (VHL) ligase binding moiety to pan GTPase KRAS (mutant) binding moiety through a linker reported to be useful for the treatment of cancer.
Waypoint Bio has raised $14.5 million in seed funding to support its work pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology.
Nanjing China-Australia Institute of Translational Medicine Co. Ltd. has disclosed baculoviral IAP repeat-containing protein 3 (BIRC3; IAP1; cIAP2), baculoviral IAP repeat-containing protein 2 (BIRC2; IAP2; cIAP1) and E3 ubiquitin-protein ligase XIAP (XIAP; BIRC4; IAP3) inhibitors reported to be useful for the treatment of cancer.
KRAS is the most commonly mutated oncogene in solid tumors. Mutations are present in about 30% of cases overall, more than 95% of pancreatic cancer cases, and about 40% of colon cancer cases.
The U.K.’s National Institute for Health and Care Excellence recent recommendation that selective internal radiation therapy could be used to treat neuroendocrine tumors that have metastasized to the liver is a boon for patients suffering from the disease. However, there is not yet a clear pathway for these patients to receive the therapy via the national health service.
As the company began a rolling NDA submission to the U.S. FDA for its drug combo in low-grade serous ovarian cancer, Verastem Oncology Inc. popped the lid off phase I/II data in pancreatic tumors, but Wall Street seemed uncertain about the news. Boston-based Verastem disclosed upbeat outcomes from the Ramp 205 study testing the RAF/MEK clamp avutometinib when paired with focal adhesion kinase inhibitor defactinib in combination with gemcitabine plus nab-paclitaxel as first-line therapy for metastatic pancreatic cancer.
Shanghai Leadingtac Pharmaceutical Co. Ltd. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.
SN Bioscience Co. Ltd., headquartered in Seongnam-si, Gyeonggi-do’s second Pangyo Valley, gained U.S. FDA fast track designation for SNB-101 (SN-38), its new polymer nanoparticle cancer drug candidate for small-cell lung cancer.
